KR20200140749A - Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata - Google Patents

Abstract

The present invention relates to a composition for preventing and treating muscular diseases, or for improving muscular functions, containing Cudrania tricuspidata, such as a crushed product or an extract of Cudrania tricuspidata as an active component. Cudrania tricuspidata such as the crushed product or the extract of Cudrania tricuspidata according to the present invention has effects of increasing the activity of mTOR involved in muscle protein synthesis, reducing the mRNA expression of MuRF-1 and atrogin-1 involved in muscle protein degradation, and thus increasing muscle mass and improving muscular functions, thereby being able to be usefully used for preventing, alleviating or treating various muscular diseases such as atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, sarcopenia, etc.

Description

Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata}

The present invention relates to a composition for improving, treating or preventing muscle disease, or improving muscle function, and more particularly, to a muscle disease containing Cudrania tricuspidata as an active ingredient such as Cudrania tricuspidata or Cudrania tricuspidata extract. It relates to a composition for improving, treating or preventing, or improving muscle function.

Muscle atrophy is caused by a gradual decrease in muscle mass, and refers to muscle weakness and degeneration (Cell, 119(7): 907-910, 2004). Muscle atrophy is promoted by inactivity, oxidative stress, and chronic inflammation and impairs muscle function and motor capacity (Clinical Nutrition, 26(5): 524-534, 2007). The most important factor in determining muscle function is muscle mass, which is maintained by a balance between protein synthesis and degradation. Muscular dystrophy occurs when protein degradation occurs more than synthetically (The International Journal of Biochemistry and Cell Biology, 37(10): 1985-1996, 2005).

Muscle size is regulated by intracellular signaling pathways that induce anabolic or catabolism occurring within the muscle. When more signaling reactions that induce synthesis occur rather than degradation of muscle protein, muscle protein synthesis is increased, which is indicated by an increase in muscle size (hypertrophy) or an increase in the number of muscle fibers (hyperplasia) according to the increase in muscle protein (The Korea Journal). of Sports Science, 20(3): 1551-1561, 2011).

Factors involved in muscle protein synthesis induce protein synthesis by phosphorylating downstream proteins from stimulation of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway in muscle cells. The activity of the mammalian target of rapamycin (mTOR) by PI3K/Akt signaling is recognized as a central growth signaling factor that integrates various growth signals in cells. mTOR contributes to muscle mass increase by inducing muscle protein synthesis by activating two factors that initiate mRNA translation, 4E-binding protein (4EBP1) and phosphorylated 70-kDa ribosomal S6 kinase (p70S6K) (The Korea Journal of Sports Science, 20(3): 1551-1561, 2011; The International Journal of Biochemistry and Cell Biology, 43(9): 1267-1276, 2011). On the other hand, when the forhead box (FoxO), a transcription factor, moves from the cytoplasm to the nucleus, it increases the expression of the E3 ubiquitin ligase factors atrogin-1 and MuRF1, which are involved in proteolysis (Disease Models and Mechanisms, 6: 25- 39, 2013). When their expression level is increased, protein breakdown in the muscle is promoted, resulting in a decrease in muscle mass. Therefore, promoting mTOR activity and inhibiting the expression of atrogin-1 and MuRF1 increase the amount of muscle protein, thereby increasing muscle mass.

Differentiation and muscle formation of muscle cells are regulated by various muscle regulatory factors. Among them, the induction of myogenin expression by MyoD activity is the most important factor in the fusion of myoblasts and is involved in the formation of myotubes. The muscle fibers formed through this process form a bundle and finally form a muscle (Cellular and Molecular Life Sciences, 70: 4117-4130, 2013).

Cudrania tricuspidata is used for traditional treatments such as eczema, pulmonary tuberculosis, chronic low back pain, and bruises, and in the private sector, it is used as a therapeutic drug for diseases such as stroke (Korean Journal of Food Science and Technology, 33(1): 128-134, 2001). Whitening of Cudrania trees (Korean Chemical Engineering Research, 52(6): 701-705, 2014), antioxidant (Korean Journal of Medicinal Crop Science, 17(2): 115-120, 2009), antibacterial (Korean Journal of Medicinal Crop Science, 17(5): 335-340, 2009) and anti-obesity (Nutrients 7(12), 10480-10490, 2015) have been reported to date.

However, prior to the present invention, it was not known about the prevention and treatment of muscle diseases, or improvement of muscle function of Cudrania tree, Cudrania tree crushed product or Cudrania tree extract.

Accordingly, the present inventors searched for a natural substance that has excellent muscle function modulating activity and can be safely applied, and as a result, Cudrania tricuspidata such as Cudrania tricuspidata is used to improve, treat or prevent muscle diseases, or The present invention was completed by confirming that there is a function improvement activity.

Accordingly, an object of the present invention is to provide a food composition for improving or preventing muscle disease, or for improving muscle function, containing Cudrania tricuspidata as an active ingredient such as Cudrania tricuspidata or Cudrania tricuspidata extract.

Another object of the present invention is to provide a pharmaceutical composition for treating or preventing muscle diseases containing Cudrania tricuspidata , such as Cudrania tricuspidata or Cudrania tricuspidata , as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for improving or preventing muscle disease, or for improving muscle function, containing Cudrania tricuspidata as an active ingredient, such as Cudrania tricuspidata or Cudrania tricuspidata extract.

Another object of the present invention is to provide a feed additive for improving or preventing muscle disease, or for improving muscle function, containing Cudrania tricuspidata as an active ingredient, such as Cudrania tricuspidata , such as Cudrania tricuspidata extract. Is to do.

In order to achieve the above object, the present invention provides a food composition for improving or preventing muscle disease, or for improving muscle function, containing Cudrania tricuspidata as an active ingredient, such as Cudrania tricuspidata or Cudrania tricuspidata extract.

In addition, the present invention provides a pharmaceutical composition for the treatment or prevention of muscle diseases containing Cudrania tricuspidata such as Cudrania tricuspidata pulverulent or Cudrania tree extract as an active ingredient.

In addition, the present invention provides a cosmetic composition for improving or preventing muscle disease, or for improving muscle function, containing Cudrania tricuspidata as an active ingredient, such as Cudrania tricuspidata or Cudrania tricuspidata extract.

In addition, the present invention provides a feed additive for improving or preventing muscle disease, or for improving muscle function, containing Cudrania tricuspidata as an active ingredient, such as Cudrania tricuspidata or Cudrania tricuspidata extract.

In addition, the present invention provides a method for treating muscle diseases by administering the composition to humans or animals other than humans.

In addition, the present invention provides a new use of Cudrania tricuspidata , such as Cudrania tricuspidata or Cudrania pulverulent pulverulent or Cudrania tree extract for the manufacture of a medicine for treating muscle diseases.

Cudrania tricuspidata , such as Cudrania tricuspidata , or Cudrania tricuspidata according to the present invention, increases the activity of mTOR involved in muscle protein synthesis, and inhibits the mRNA expression of MuRF1 and atrogin-1, which are involved in muscle protein degradation. It has an excellent effect on making. In addition, by increasing muscle mass and improving muscle function, it is possible to prevent, treat or improve muscle function decline and muscle loss caused by various diseases. Since the present invention is a natural product, it can be safely used without side effects, and thus can be used as pharmaceuticals, foods or cosmetics.

1 is a result of confirming the effect of increasing the activity of mTOR according to the ethanol extract treatment of Cudrania leaves in L6 muscle cells.
2 is a result of confirming the effect of reducing the mRNA expression levels of atrogin-1 and MuRF1 according to treatment with hot water or ethanol extract from Cudrania tree leaves in L6 muscle cells.
3 is a result of confirming the effect of reducing the mRNA expression levels of atrogin-1 and MuRF1 according to hot water or ethanol extract treatment of Cudrania fruit in L6 muscle cells.
4 is a result of confirming the effect of reducing the mRNA expression levels of atrogin-1 and MuRF1 according to hot water or ethanol extract treatment of Cudrania tree branch in L6 muscle cells.
5 is a result of confirming the effect of improving muscle strength according to treatment with 50% ethanol extract of Cudrania leaves in the muscle atrophy-induced rat.
6 is a result of confirming the effect of increasing muscle volume according to treatment with 50% ethanol extract of Cudrania leaves in the muscle atrophy-induced rat.
7 is a result of confirming the effect of increasing the weight of tibialis anterior muscle according to treatment with 50% ethanol extract of Cudrania leaves in the muscle atrophy-induced rat.

Hereinafter, the configuration of the present invention will be described in detail.

The present invention is Cudrania tricuspidata , such as Cudrania tricuspidata or Cudrania tricuspidata , for improving or preventing muscle disease, or a food composition for improving muscle function; Cudrania tricuspidata , such as Cudrania tricuspidata crushed product or Cudrania tricuspidata , a pharmaceutical composition for the treatment or prevention of muscle diseases; Or Cudrania tricuspidata , such as Cudrania tricuspidata pulverized product or Cudrania tricuspidata , for improving or preventing muscle disease, or a cosmetic composition for improving muscle function; Or Cudrania tricuspidata , such as Cudrania tricuspidata or Cudrania tricuspidata , for improving or preventing muscle diseases, or feed additives for improving muscle function; Or it provides a method for treating muscle diseases comprising applying Cudrania tricuspidata such as Cudrania tricuspidata or Cudrania tricuspidata to humans or non-human mammals.

In the present specification, the'cudrania tree' belongs to the Moraceae family, and is a leaf, fruit, branch or mixture thereof of Cudrania tricuspidata , and is a pulverized Cudrania tree or an extract of Cudrania tree.

In the present specification, the'Cultured Cudrania tree' refers to mammals, including humans, according to a method by which a person of ordinary skill in the art can easily implement dried leaves, fruits, or branches of Cudrania. While this can be easily ingested, it can be prepared and used in a form in which the active ingredient is easily released from the dried pulverized material in the intestine after ingestion and, as a result, can be easily absorbed into the mammalian body. For this purpose, the shape or size of the dried pulverized particles is not limited, but as the surface of the particles is maximized, the glass of the active ingredients described above is easier, so it is preferable to prepare them in a fine powder form. In one embodiment of the present invention, dried Cudrania leaves, fruits, or branches were pulverized with a mixer to prepare a pulverized product.

In the present specification, the'Kuji mulberry extract' is obtained by extracting the leaves, fruits, or branches of the Cudrania tree using a suitable solvent, and an extract, a dilution or concentrate of the extract, a dried product obtained by drying the extract, or a preparation thereof Or it includes all the form of a purified product. The manufacturing method of Cudrania tree extract may be obtained by extracting from Cudrania tree with water, an organic solvent having 1 to 6 carbon atoms, and one or more solvents selected from the group consisting of ultra-high pressure, subcritical or supercritical fluid, but is not limited thereto.

Cudrania tree extract of the present invention can be prepared using conventional extraction methods in the industry, such as heat extraction, cold needle extraction, ultrasonic extraction, filtration and reflux extraction, and the Cudrania tree is commercially available for purchase and use, or in nature. You can use harvested or grown ones.

The Cudrania tree extract according to the present invention can be separated using a conventional solvent under conditions of a conventional temperature and pressure according to a conventional method known in the art for preparing an extract from a natural product.

The term "fraction" as used herein refers to a product obtained by a fractionation method for separating a specific component or specific group from a mixture containing various components. In the present invention, it means the result obtained by the fractionation method for separating a specific component or a specific group from the Cudrania tree extract prepared as described above.

In order to obtain the Cudrania tree fraction according to the present invention, conventional fractionation solvents known in the art, for example, polar solvents such as anhydrous or water-containing lower alcohols having 1 to 4 carbon atoms such as water, ethanol, and methanol, and hexane, butanol, Non-polar solvents such as ethyl acetate, chloroform, and dichloromethane, or a mixed solvent thereof may be used, but are not limited thereto.

The Cudrania tree fraction of the present invention may include those obtained by additionally applying a purification process. For example, the fraction obtained by passing the Cudrania tree extract according to the present invention through an ultrafiltration membrane having a constant molecular weight cut-off value, various chromatography (size, charge, hydrophobicity or affinity) Fractions obtained through various purification methods additionally carried out by separation by (produced for separation) are also included in the Cudrania tree extract of the present invention.

In the present specification,'muscle' refers to tendons, muscles, and tendons generically, and'muscle function' refers to the ability to exert power by contraction of muscles, and the muscles can exert their contractile force as much as possible to overcome resistance. It includes muscle strength, which is the ability to be capable, muscle endurance, which is the ability to repeat contractions and relaxations for a given weight, for how long or many times, and quickness, which is the ability to exert strong power in a short time. The term "improving muscle function" in the present specification refers to improving muscle function better by increasing muscle mass.

The present invention is a pharmaceutical composition for preventing and treating muscle diseases, or for improving muscle function, comprising a Cudrania tree, Cudrania tree crushed product or Cudrania tree extract as an active ingredient; Food composition for preventing and improving muscle disease, or for improving muscle function; It provides a cosmetic composition for preventing and improving muscle disease, or for improving muscle function.

In one embodiment, the Cudrania tree extract may be hot water extract, ethanol extract, ethyl acetate extract, hexane extract, ultra-high pressure extract, subcritical extract, supercritical extract, but is not limited thereto.

In one embodiment, Cudrania tree extract can be obtained by extracting leaves, fruits, and branches of Cudrania tree with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical and supercritical fluid. . Cudrania tree can also be obtained by extraction under conditions of ultra-high pressure of 100 MPa or more. If necessary, it can be prepared by additionally including filtration and concentration steps according to methods known in the art.

In one embodiment, the organic solvent having 1 to 6 carbon atoms is an alcohol having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, It may be at least one selected from the group consisting of methylene chloride, hexane, cyclohexane, and petroleum ether.

In a specific embodiment of the present invention, the present inventors repeatedly extract the pulverized product of dried Cudrania leaves, fruits, and branches at room temperature using ethanol, ethyl acetate and hexane as a solvent, or hot water extraction, ultra high pressure extraction, subcritical Cudrania tree extract was prepared using fluid extraction.

50% and 100% ethanol extracts of the prepared Cudrania leaves, fruits, and branches were treated on L6 muscle cells, respectively, and as a result of confirming the activity exhibited in muscle cells, the protein expression of p-mTOR involved in muscle protein synthesis was significant. It was confirmed that it is increased to (Fig. 1). In addition, it was confirmed that ethyl acetate extract, hexane extract, ultra-high pressure extract, subcritical extract, and supercritical extract of Cudrania chinensis significantly increased the protein expression of p-mTOR in L6 muscle cells (Table 1). In addition, as a result of processing the hot water and ethanol extracts of Cudrania tree leaves, fruits, branches, respectively, on L6 muscle cells, the activity exhibited in muscle cells was confirmed. As a result, mRNA expression of MuRF-1 and atrogin-1 involved in muscle protein degradation It was confirmed that it was suppressed (Figs. 2 to 4).

As a result of treatment with 50% ethanol from Cudrania leaves using an immobilization mouse animal model using a skin stapler, muscle strength, muscle volume, and muscle weight were significantly increased compared to the control group (FIGS. 5 to 7 ). In addition, as a result of treatment of Cudrania tree leaf crushed product, leaf hot water extract, fruit crushed product, fruit hot water extract, eggplant crushed product, and eggplant hot water extract, muscle strength and muscle weight were significantly higher in each treatment group than the control group. It was confirmed that it is increased (Table 2).

When the composition for preventing and treating muscle diseases of the present invention is a pharmaceutical composition, it can be used for preventing or treating muscle diseases caused by muscle wasting or degeneration. Muscle wasting and degeneration occurs due to genetic factors, acquired factors, aging, etc., and muscle wasting is characterized by a gradual loss of muscle mass, weakness and degeneration of muscles, especially skeletal or voluntary muscles and heart muscles. Examples of related diseases include atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia. The composition of the present invention has an effect of increasing muscle mass, and the type of muscle is not limited.

The pharmaceutical composition for preventing and treating muscle diseases of the present invention or improving muscle function may include a pharmaceutically acceptable carrier.

The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, the carrier for parenteral administration may include water, suitable oil, saline, aqueous glucose and glycol. In addition, it may further comprise a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives are benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Other pharmaceutically acceptable carriers may be referred to as those described in the following literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).

The pharmaceutical composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally, and parenteral administration methods are not limited thereto, but intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal , Intranasal, intestinal, topical, sublingual or rectal administration.

The pharmaceutical composition of the present invention may be formulated as a formulation for oral administration or parenteral administration according to the route of administration as described above. When formulated, one or more buffers (e.g., saline or PBS), antioxidants, bacteriostatic agents, chelating agents (e.g., EDTA or glutathione), fillers, bulking agents, binders, adjuvants (e.g., aluminum hydroxide). Side), suspending agents, thickening agents, wetting agents, disintegrants or surfactants, diluents or excipients.

Solid preparations for oral administration include tablets, pills, powders, granules, liquids, gels, syrups, slurries, suspensions or capsules, and the like, and such solid preparations are at least one excipient in the pharmaceutical composition of the present invention, for example , Starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol maltitol, cellulose , Methyl cellulose, sodium carboxymethylcellulose, and hydroxypropylmethyl-cellulose or gelatin may be mixed and prepared. For example, tablets or sugar tablets can be obtained by blending the active ingredient with a solid excipient, pulverizing it, adding a suitable auxiliary, and processing into a granule mixture.

In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, liquid solutions, emulsions, or syrups, but may include various excipients, such as wetting agents, sweetening agents, fragrances, or preservatives, in addition to water or liquid paraffin, which are simple diluents commonly used. .

In addition, in some cases, cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as a disintegrant, and an anti-coagulant, a lubricant, a wetting agent, a fragrance, an emulsifier and a preservative may be additionally included. .

When administered parenterally, the pharmaceutical composition of the present invention may be formulated according to a method known in the art in the form of an injection, a transdermal administration, and a nasal inhalation agent together with a suitable parenteral carrier. In the case of such injections, they must be sterilized and protected from contamination by microorganisms such as bacteria and fungi. Examples of suitable carriers for injections include, but are not limited to, water, ethanol, polyols (e.g., glycerol, propylene glycol and liquid polyethylene glycol, etc.), mixtures thereof and/or solvents or dispersion media containing vegetable oils. I can. More preferably, suitable carriers include Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) containing triethanolamine or sterile water for injection, isotonic solutions such as 10% ethanol, 40% propylene glycol and 5% dextrose. Etc. can be used. In order to protect the injection from microbial contamination, various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid, thimerosal, and the like may be additionally included. In addition, the injection may further include an isotonic agent such as sugar or sodium chloride in most cases.

In the case of transdermal administration, ointments, creams, lotions, gels, external solutions, pasta, liniment, and air rolls are included. In the above, "transdermal administration" means that an effective amount of the active ingredient contained in the pharmaceutical composition is delivered into the skin by topically administering the pharmaceutical composition to the skin.

In the case of inhalation dosages, the compounds used according to the invention can be prepared using a suitable propellant, for example dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas, pressurized pack or It can be conveniently delivered from a nebulizer in the form of an aerosol spray. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve that delivers a metered amount. For example, gelatin capsules and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mixture of the compound and a suitable powder base such as lactose or starch. Formulations for parenteral administration are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a formula generally known for all pharmaceutical chemistry.

The pharmaceutical composition for preventing and treating muscle diseases of the present invention, or for improving muscle function, may provide a desirable muscle disease prevention and treatment effect, or improvement in muscle function when an effective amount of Cudrania chinensis extract is included. In the present specification, the term'effective amount' refers to an amount that exhibits a higher response compared to the negative control group, and preferably refers to an amount sufficient to improve muscle function. The pharmaceutical composition of the present invention may contain 0.01 to 99.99% of Cudrania tree extract, and the balance may be occupied by a pharmaceutically acceptable carrier. The effective amount of the Cudrania tree extract contained in the pharmaceutical composition of the present invention will vary depending on the form in which the composition is commercialized.

The total effective amount of the pharmaceutical composition of the present invention may be administered to a patient in a single dose, and may be administered by a fractionated treatment protocol that is administered for a long time in multiple doses. The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the severity of the disease. When parenterally administered, it is preferably administered in an amount of 0.01 to 50 mg, more preferably 0.1 to 30 mg per 1 kg of body weight per day based on the Cudrania tree extract, and when administered orally, based on the Cudrania tree extract per day. In order to be administered in an amount of preferably 0.01 to 100 mg, more preferably 0.01 to 10 mg per 1 kg of body weight, it may be divided into 1 to several times. However, the dose of the Cudrania tree extract is determined by taking into account various factors such as the patient's age, weight, health status, sex, disease severity, diet and excretion rate, as well as the administration route and number of treatments of the pharmaceutical composition. Therefore, considering these points, those of ordinary skill in the art will be able to determine an appropriate effective dosage of the Cudrania tree extract according to a specific use for preventing and treating muscle diseases. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, route of administration, and method of administration as long as it exhibits the effects of the present invention.

The pharmaceutical composition for preventing and treating muscle diseases of the present invention, or for improving muscle function, may be used alone or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, or methods using biological response modifiers.

The pharmaceutical composition for preventing and treating muscle diseases of the present invention or for improving muscle function may also be provided in the form of an external preparation containing a Cudrania tree extract as an active ingredient.

When the pharmaceutical composition for preventing and treating muscle diseases of the present invention or for improving muscle function is used as an external application for skin, additionally fatty substances, organic solvents, solubilizers, thickening agents and gelling agents, emollients, antioxidants, suspending agents, stabilizers Agents, foaming agents, fragrances, surfactants, water, ionic emulsifiers, nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, It may contain an adjuvant commonly used in the field of dermatology such as a hydrophilic activator, a lipophilic activator, or any other ingredients commonly used in skin external preparations such as lipid vesicles. In addition, the above ingredients may be introduced in amounts generally used in the field of dermatology.

When the pharmaceutical composition for preventing and treating muscle diseases of the present invention or for improving muscle function is provided as an external application for skin, it may be a formulation such as an ointment, patch, gel, cream, or spray, but is not limited thereto.

The composition for preventing and improving muscle disease of the present invention or for improving muscle function may also be a food composition. In the case of a food composition for preventing and improving muscle disease or improving muscle function of the present invention, it may be used for preventing or improving muscle disease due to muscle wasting or degeneration. Muscle wasting and degeneration occurs due to genetic factors, acquired factors, aging, etc., and muscle wasting is characterized by a gradual loss of muscle mass, weakness and degeneration of muscles, especially skeletal or voluntary muscles and heart muscles. Examples of related diseases include atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia. The composition of the present invention has an effect of increasing muscle mass, and the type of muscle is not limited.

The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food, food additives and feed, and contains humans or animals including livestock. It is targeted for eating. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.

Food compositions of this type can be prepared in various forms according to conventional methods known in the art. General foods include, but are not limited to, beverages (including alcoholic beverages), fruits and processed foods thereof (e.g., canned fruit, canned food, jam, marmalade, etc.), fish, meat and processed foods thereof (e.g. ham, sausage) Corn beef), bread and noodles (e.g. udon, buckwheat noodles, ramen, spagate, macaroni, etc.), fruit juice, various drinks, cookies, sweets, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine , Vegetable protein, retort food, frozen food, various seasonings (eg, soybean paste, soy sauce, sauce, etc.), etc. can be prepared by adding Cudrania tree, Cudrania tree crushed product or Cudrania tree extract. In addition, as a nutritional supplement, it is not limited thereto, but may be prepared by adding Cudrania tree, Cudrania tree crushed product, or Cudrania tree extract to capsules, tablets, and pills. In addition, the health functional food is not limited thereto, for example, liquefied and granulated so that it can be drinkable (health drink) by manufacturing Cudrania tree, Cudrania tree crushed product or Cudrania tree extract itself in the form of tea, juice, and drink. , Encapsulated and powdered to be ingested. In addition, in order to use Cudrania tree, Cudrania tree crushed product, or Cudrania tree extract in the form of a food additive, it may be prepared and used in the form of a powder or concentrate. In addition, it can be prepared in the form of a composition by mixing with a Cudrania tree, Cudrania tree crushed product or Cudrania tree extract and a known active ingredient known to have an effect of preventing and improving muscle disease or improving muscle function.

When the composition for preventing and improving muscle disease or improving muscle function of the present invention is used as a health drink composition, the health drink composition may contain various flavoring agents or natural carbohydrates as an additional component, such as a conventional beverage. . The natural carbohydrates described above include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin and cyclodextrin; It may be a sugar alcohol such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as taumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.

Cudrania tree, Cudrania tree crushed product, Cudrania tree extract may be contained as an active ingredient in a food composition for preventing and improving muscle disease, or improving muscle function, the amount of which is for preventing and improving muscle disease, or for improving muscle function It is not particularly limited to an amount effective to achieve, but is preferably 0.01 to 100% by weight based on the total weight of the total composition. The food composition of the present invention may be prepared by mixing with other active ingredients known to be effective in preventing and improving muscle diseases, or improving muscle function together with Cudrania, Cudrania japonica pulverulent, Cudrania japonica extract.

In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, It may contain glycerin, alcohol or a carbonating agent. In addition, the health food of the present invention may contain flesh for the manufacture of natural fruit juice, fruit juice beverage, or vegetable beverage. These ingredients may be used independently or in combination. The ratio of these additives is not very important, but it is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

The composition for preventing and improving muscle disease or improving muscle function of the present invention may also be a cosmetic composition. The cosmetic composition of the present invention contains Cudrania tree, Cudrania tree crushed product or Cudrania tree extract as an active ingredient, and basic cosmetic compositions (face wash, such as lotion, cream, essence, cleansing foam and cleansing water, with dermatologically acceptable excipients, Pack, body oil), color cosmetic composition (foundation, lipstick, mascara, makeup base), hair product composition (shampoo, conditioner, hair conditioner, hair gel), and soap.

The excipient is not limited thereto, but may include, for example, an emollient, a skin penetration enhancer, a colorant, a fragrance, an emulsifier, a thickener, and a solvent. In addition, flavoring, coloring, disinfecting agents, antioxidants, preservatives, moisturizing agents, etc. may be additionally included, and thickeners, inorganic salts, synthetic polymer materials, etc. may be included for the purpose of improving physical properties. For example, in the case of preparing a face wash and soap with the cosmetic composition of the present invention, it can be easily prepared by adding Cudrania tree, Cudrania tree crushed product, or Cudrania tree extract to a conventional face wash and soap base. In the case of producing a cream, it can be prepared by adding Cudrania, pulverulent or Cudrania mulberry extract to a cream base of a general oil-in-water (O/W) type. Synthetic or natural materials such as proteins, minerals, vitamins, etc. for the purpose of improving physical properties, such as fragrances, chelating agents, coloring agents, antioxidants, preservatives, etc., may be additionally added.

The content of Cudrania tree, Cudrania tree crushed product or Cudrania tree extract contained in the cosmetic composition of the present invention is not limited thereto, but is preferably 0.001 to 10% by weight, and more preferably 0.01 to 5% by weight based on the total weight of the composition. Do. When the content is less than 0.001% by weight, the desired anti-aging or wrinkle improvement effect cannot be expected, and when the content is more than 10% by weight, there may be difficulties in safety or formulation.

The composition of the present invention may be added to a feed additive or a feed composition containing the same for the purpose of preventing or improving muscle disease.

In the present invention, the term "feed additive" is a substance added to feed for the purpose of various effects such as supplementing nutrients and preventing weight loss, improving the digestibility of fiber in feed, improving oil quality, preventing reproductive disorders and improving conception rate, and preventing high temperature stress in summer Includes. The feed additive of the present invention corresponds to an auxiliary feed in the feed management method, and minerals such as sodium hydrogen carbonate, bentonite, magnesium oxide, complex minerals, minerals such as zinc, copper, cobalt, selenium, etc. , Vitamins such as vitamin AD, E, nicotinic acid, and vitamin B complex, protective amino acids such as methionine and lysine, protective fatty acids such as fatty acid calcium salts, probiotics (lactic acid bacteria), yeast cultures, live bacteria such as fungal fermentation products, Yeast agents and the like may additionally be included.

In the present invention, the term "feed" is any natural or artificial diet for eating, ingesting, digesting, or suitable therefor, or as a component of the single meal, for preventing or improving muscle diseases according to the present invention. The feed containing the composition as an active ingredient can be prepared in various types of feed known in the art, and preferably includes a rich feed, a roughage and/or a special feed, but is not limited thereto.

Rich feed includes seed fruits, including grains such as wheat, oats, and corn, and by-products obtained by refining grains, such as rice bran, bran, and barley bran, including rice bran, soybeans, fluids, sesame seeds, flax seeds, and coco palms. It is a concentrated product of sesame cakes, sweet potatoes, potatoes, and other residues such as residual starch, which is the main component of starch residue, fish meal, fish residue, and fresh liquids obtained from fish. Animal feed such as dry whey, which is the balance when making casein from fish soluble, blood meal, feather powder, skim milk powder, cheese from milk, and casein from skim milk, yeast, There are chlorella and seaweed, but are not limited thereto.

Forage, raw grasses, grasses, and green grass feed, turnips for feed, beets for feed, root vegetables such as Luther Bearger, a kind of turnip, raw grasses, green crops, grains, etc., are placed in a silo. There are silage, which is a stored feed that has been filled and fermented with lactic acid, wild grass, hay that has been cut and dried, straw for breeding crops, and leaves of legumes, but is not limited thereto. In special feeds, mineral feeds such as oyster shells and rock salts, urea feeds such as urea and its derivatives, Diureide isobutane, and ingredients that are likely to be insufficient when only natural feed ingredients are blended, or blended feeds to increase the storage properties of feed. There are feed additives and dietary supplements, which are substances added in trace amounts, but are not limited thereto.

The feed additive for preventing or improving muscle disease according to the present invention can be prepared by adding Pukuji mulberry, Cudrania pulverulent or Cudrania tree extract in an appropriate effective concentration range according to various feed manufacturing methods known in the art.

The feed additive according to the present invention can be applied without limitation if it is an individual for the purpose of preventing or improving muscle disease. For example, it can be applied to any individual such as non-human animals such as cattle, horses, pigs, goats, sheep, dogs, cats, rabbits, etc., birds and fish.

Hereinafter, the present invention will be described in more detail through examples.

However, the following examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following examples.

[Example 1] Preparation of Cudrania tree leaf extract

<1-1> Preparation of hot water extract of Cudrania tree leaves

The dried Cudrania leaves were pulverized with a mixer, and then 10 g of the crushed Cudrania leaves samples were added to 100 mL of water and extracted at 80°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and a hot water extract of Cudrania leaves was obtained.

<1-2> Preparation of 30% ethanol extract from Cudrania tree leaves

The dried Cudrania leaves were pulverized with a mixer, and then 10 g of the pulverized Cudrania leaves samples were added to 100 mL of 30% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a 30% ethanol extract of Cudrania leaves was obtained. The 30% ethanol extract refers to an extract extracted with a mixed solvent of 30% by weight of ethanol in 70% by weight of water.

<1-3> Preparation of 50% ethanol extract from Cudrania tree leaves

The dried Cudrania leaves were pulverized with a mixer, and then 10 g of the crushed Cudrania leaves samples were added to 100 mL of 50% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a 50% ethanol extract of Cudrania leaves was obtained.

<1-4> Preparation of 70% ethanol extract of Cudrania tree leaves

The dried Cudrania leaves were pulverized with a mixer, and then 10 g of the crushed Cudrania leaves samples were added to 100 mL of 70% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a 70% ethanol extract of Cudrania leaves was obtained.

<1-5> Preparation of 100% ethanol extract of Cudrania leaves

The dried Cudrania leaves were pulverized with a mixer, and then 10 g of the crushed Cudrania leaves samples were added to 100 mL of 100% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then 100% ethanol extract of Cudrania leaves was obtained.

<1-6> Preparation of Ethyl Acetate Extract from Cudrania Tree Leaf

The dried Cudrania leaves were pulverized with a mixer, and then 10 g of the crushed Cudrania leaves samples were added to 100 mL of ethyl acetate and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component to obtain an ethyl acetate extract from Cudrania tree leaves.

<1-7> Preparation of hexane extract from Cudrania tree leaves

The dried Cudrania leaves were pulverized with a mixer, and then 10 g of the crushed Cudrania leaves samples were added to 100 mL of hexane and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a hexane extract of Cudrania leaves was obtained.

<1-8> Preparation of ultra-high pressure extract of Cudrania tree leaves

After crushing the dried Cudrania leaves with a mixer, 1 g of the crushed Cudrania leaves and 76 mL of 18% ethanol are put in a polyethylene pack, sealed, and then using an ultra-high pressure extraction device (Frescal MFP-7000; Mitsubishi Heavy Industries). And extracted. In the ultra-high pressure extraction conditions, the extraction pressure was 320 MPa and the extraction time was 5 min. The extracted sample was filtered through Whatman No. 2 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, thereby obtaining an ultra-high pressure extract of Cudrania leaves.

<1-9> Preparation of subcritical extract of Cudrania tree leaves

The dried Cudrania leaves were pulverized with a mixer, and then 50 g of the crushed Cudrania leaves were put into a subcritical water reactor of a subcritical extractor (Biovan, Gyeonggi, Korea) with 1 L of water and sealed. After sealing, the temperature of the reactor was raised to 200° C., and when the temperature of the reactor reached 200° C., heating was stopped, and the temperature was maintained for 20 minutes to perform extraction. After 20 minutes, the extract was transferred to a storage tank supplied with cooling water, rapidly cooled to 30° C., and then centrifuged at 3,600 rpm for 30 minutes to separate the floating residue, and only the supernatant was taken. A lyophilizer (Ilshin Lab Co. Ltd., Seoul, Korea) was used to remove all of the solvent to obtain a subcritical extract of Cudrania leaves.

<1-10> Preparation of supercritical extract of Cudrania tree leaves

The dried Cudrania leaves were pulverized with a mixer, and then 10 g of the pulverized Cudrania leaves were filled in a sample cartridge and extracted using a supercritical fluid extraction device (SFX 3560, Isco Inc., Lincoln, NE, USA). In the supercritical extraction conditions, the extraction pressure was 300 bar, the extraction temperature was 50°C, the flow rate of supercritical carbon dioxide was 60 mL/min, and the extraction time was 2 hours. When the supercritical fluid extraction was completed, the pressure of the extraction device was lowered to release the supercritical fluid state to obtain a supercritical extract of Cudrania leaves.

[Example 2] Preparation of Cudrania tree fruit extract

<2-1> Preparation of hot water extract of Cudrania tree fruit

The dried Cudrania fruit was pulverized with a mixer, and then 10 g of the pulverized Cudrania fruit sample was added to 100 mL of water and extracted at 80°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a hot water extract of Cudrania fruit was obtained.

<2-2> Preparation of 30% ethanol extract of Cudrania tree fruit

The dried Cudrania fruit was pulverized with a mixer, and then 10 g of the pulverized Cudrania fruit sample was added to 100 mL of 30% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and a 30% ethanol extract of Cudrania fruit was obtained.

<2-3> Preparation of 50% ethanol extract of Cudrania tree fruit

The dried Cudrania fruit was pulverized with a mixer, and then 10 g of the pulverized Cudrania fruit sample was added to 100 mL of 50% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and a 50% ethanol extract of Cudrania fruit was obtained.

<2-4> Preparation of 70% ethanol extract of Cudrania tree fruit

The dried Cudrania fruit was pulverized with a mixer, and then 10 g of the pulverized Cudrania fruit sample was added to 100 mL of 70% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a 70% ethanol extract of Cudrania fruit was obtained.

<2-5> Preparation of 100% ethanol extract of Cudrania tree fruit

The dried Cudrania fruit was pulverized with a mixer, and then 10 g of the pulverized Cudrania fruit sample was added to 100 mL of 100% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then 100% ethanol extract of Cudrania tree fruit was obtained.

<2-6> Preparation of ultra-high pressure extract of Cudrania tree fruit

After crushing the dried Cudrania fruit with a mixer, 1 g of the crushed Cudrania fruit and 76 mL of 18% ethanol are put in a polyethylene pack, sealed, and then using an ultra-high pressure extraction device (Frescal MFP-7000; Mitsubishi Heavy Industries). And extracted. In the ultra-high pressure extraction conditions, the extraction pressure was 320 MPa and the extraction time was 5 min. The extracted sample was filtered through Whatman No. 2 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, thereby obtaining an ultra-high pressure extract of Cudrania fruit.

<2-7> Preparation of subcritical extract of Cudrania tree fruit

After pulverizing the dried Cudrania fruit with a mixer, 50 g of the crushed Cudrania fruit was put into a subcritical water reactor of a subcritical extraction apparatus (Biovan, Gyeonggi, Korea) with 1 L of water and sealed. After sealing, the temperature of the reactor was raised to 200° C., and when the temperature of the reactor reached 200° C., heating was stopped, and the temperature was maintained for 20 minutes to perform extraction. After 20 minutes, the extract was transferred to a storage tank supplied with cooling water, rapidly cooled to 30° C., and then centrifuged at 3,600 rpm for 30 minutes to separate the floating residue, and only the supernatant was taken. By removing all of the solvent using a freeze dryer (Ilshin Lab Co. Ltd., Seoul, Korea), a subcritical extract of Cudrania fruit was obtained.

<2-8> Preparation of supercritical extract of Cudrania tree fruit

After pulverizing the dried Cudrania fruit with a mixer, 10 g of the pulverized Cudrania fruit was filled in a sample cartridge and extracted using a supercritical fluid extraction device (SFX 3560, Isco Inc., Lincoln, NE, USA). In the supercritical extraction conditions, the extraction pressure was 300 bar, the extraction temperature was 50°C, the flow rate of supercritical carbon dioxide was 60 mL/min, and the extraction time was 2 hours. When the supercritical fluid extraction was completed, the pressure of the extraction device was lowered to release the supercritical fluid state to obtain a Cudrania fruit supercritical extract.

[Example 3] Preparation of Cudrania tree branch extract

<3-1> Preparation of hot water extract of Cudrania tree branch

The dried Cudrania branch was pulverized with a mixer, and then 10 g of the pulverized Cudrania branch sample was added to 100 mL of water and extracted at 80°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a hot water extract of Cudrania tree branch was obtained.

<3-2> Preparation of 30% ethanol extract of Cudrania tree branch

The dried Cudrania branch was pulverized with a mixer, and then 10 g of the pulverized Cudrania branch sample was added to 100 mL of 30% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a 30% ethanol extract of Cudrania tree branch was obtained.

<3-3> Preparation of 50% ethanol extract of Cudrania tree branch

The dried Cudrania branch was pulverized with a mixer, and then 10 g of the pulverized Cudrania branch sample was added to 100 mL of 50% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a 50% ethanol extract of Cudrania tree branch was obtained.

<3-4> Preparation of 70% ethanol extract of Cudrania tree branch

The dried Cudrania branch was pulverized with a mixer, and then 10 g of the pulverized Cudrania branch sample was added to 100 mL of 70% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then a 70% ethanol extract of Cudrania tree branch was obtained.

<3-5> Preparation of 100% ethanol extract of Cudrania tree branch

The dried Cudrania branch was crushed with a mixer, and then 10 g of the pulverized Cudrania branch sample was added to 100 mL of 100% ethanol and extracted at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then 100% ethanol extract of Cudrania tree branch was obtained.

<3-6> Preparation of ultra-high pressure extract of Cudrania tree branch

After crushing the dried Cudrania branch with a mixer, 1 g of the crushed Cudrania tree branch and 76 mL of 18% ethanol are put in a polyethylene pack, sealed, and then using an ultra-high pressure extraction device (Frescal MFP-7000; Mitsubishi Heavy Industries). And extracted. In the ultra-high pressure extraction conditions, the extraction pressure was 320 MPa and the extraction time was 5 min. The extracted sample was filtered through Whatman No. 2 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, thereby obtaining an ultra-high pressure extract of Cudrania tree branch.

<3-7> Preparation of subcritical extract of Cudrania tree branch

After pulverizing the dried Cudrania tree branches with a mixer, 50 g of the crushed Cudrania tree branches were put into a subcritical water reactor of a subcritical extraction device (Biovan, Gyeonggi, Korea) with 1 L of water and sealed. After sealing, the temperature of the reactor was raised to 200° C., and when the temperature of the reactor reached 200° C., heating was stopped, and the temperature was maintained for 20 minutes to perform extraction. After 20 minutes, the extract was transferred to a storage tank supplied with cooling water, rapidly cooled to 30° C., and then centrifuged at 3,600 rpm for 30 minutes to separate the floating residue, and only the supernatant was taken. A freeze dryer (Ilshin Lab Co. Ltd., Seoul, Korea) was used to remove all of the solvent to obtain a subcritical extract of Cudrania tree branch.

<3-8> Preparation of supercritical extract of Cudrania tree branch

The dried Cudrania branch was pulverized with a mixer, and then 10 g of the pulverized Cudrania branch was filled into a sample cartridge and extracted using a supercritical fluid extraction device (SFX 3560, Isco Inc., Lincoln, NE, USA). In the supercritical extraction conditions, the extraction pressure was 300 bar, the extraction temperature was 50°C, the flow rate of supercritical carbon dioxide was 60 mL/min, and the extraction time was 2 hours. When the supercritical fluid extraction was completed, the pressure of the extraction device was lowered to release the supercritical fluid state to obtain a supercritical extract of Cudrania tree branch.

[Example 4] Effect of Promoting Muscle Protein Synthesis of Ethanol Extract of Cudrania Tree

When mTOR protein is phosphorylated and activated, it is known that it can induce activation of proteins involved in muscle protein synthesis and muscle mass increase in the PI3K/Akt signaling pathway in muscle cells. Thus, in order to confirm the muscle production induction activity of Cudrania, mTOR was confirmed using the mTOR Sandwich ELISA kit (Cell Signaling Technology, Beverly, MA, USA).

1 × L6 myoblasts (ATCC; Manassas, VA, USA) in a 6-well plate with Dulbecco's modified Eagle's media (DMEM; Hyclone) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA). After seeding to become 10 ⁵ cells/well, it was cultured for 24 hours. After incubation, the medium in the wells was removed, exchanged with DMEM (Hyclone) containing 2% horse serum (HS; Hyclone), and cultured for an additional 6 days to differentiate L6 cells into myotubes. Next, the Cudrania tree leaf 50% ethanol extract of Example 1-3, the Cudrania tree leaf 100% ethanol extract of Example 1-5, the Cudrania tree fruit 50% ethanol extract of Example 2-3, Example 2-3 After dissolving 100% ethanol extract of Cudrania fruit, 50% ethanol extract of Cudrania tree branch of Example 3-3, and 100% ethanol extract of Cudrania tree branch of Example 3-5 in DMEM (Hyclone) by 40 μg/mL , Cells were treated and incubated for 12 hours. After incubation, cells were lysed by treatment with a cell lysis buffer. Protein in the obtained cell lysate was quantified at a concentration of 1 mg/mL using Bradford (Bio-Rad Laboratories Inc., Hercules, CA, USA). 50 μL of cell lysate was dispensed into microwells to which the anti-mTOR antibody was attached, and left at 37° C. for 2 hours. After washing a total of 4 times with a washing buffer, the detection antibody was treated and left for 1 hour at 37°C. After washing a total of 4 times with a washing buffer, horseradish peroxidase ) Was added to the conjugated secondary antibody and allowed to stand at 37°C for 30 minutes. Finally, after washing a total of 4 times with the washing buffer solution, the TMB substrate was added to each well and allowed to stand at 37°C for 10 minutes, and a stop solution was added to stop the reaction of TMB. After 2 minutes, the absorbance was measured with a wavelength of 450 nm to measure the mTOR level in the root canal cells treated with the Cudrania tree leaf extract. The experiment was repeated a total of 3 times, and each obtained measured value was expressed as mean±standard deviation by calculating the percentage (%) for the control group. Differences between groups were confirmed through Duncan multi-range analysis by one-way analysis of variance using the SPSS25.0 statistical package (SPSS Inc., Chicago, IL, USA). In this case, when the p value is less than 5%, it is marked as statistically significant.

As a result, it was confirmed that the activity of mTOR was significantly increased ( ^** p <0.01) compared to the control group not treated with the extract as the ethanol extracts of Cudrania leaves, fruits and stems were treated as shown in FIG. 1 . This means that the ethanol extract of Cudrania leaves, fruit and stem of the present invention has excellent ability to promote muscle protein synthesis in muscle cells.

[Example 5] Effect of Promoting Muscle Protein Synthesis of Cudrania Tree Extract

Cudrania leaf ethyl acetate, hexane, ultra-high pressure, subcritical, and supercritical extracts of Examples 1-6 to 1-10; Cudrania fruit super-high pressure, subcritical, supercritical extracts of Examples 2-6 to 2-8; The mTOR activity was measured in the same manner as in Example 1, except that the ultra-high pressure, subcritical, and supercritical extracts of Cudrania tree trunks of Examples 3-6 to 3-8 were each treated with 40 μg/mL. .

As a result, as shown in Table 1, it was confirmed that, as compared to the control group not treated with the extract, the activity of mTOR increased significantly ( ^** p <0.01) by treating the Cudrania tree extract. This means that the Cudrania tree extract of the present invention has excellent ability to promote muscle protein synthesis in muscle cells.

Experimental group Relative mTOR activity (%) Example 1-6 127.6±2.2** Example 1-7 126.1±1.9** Example 1-8 131.8±4.0** Example 1-9 130.5±1.7** Example 1-10 132.6±3.8** Example 2-6 122.5±3.9** Example 2-7 116.0±2.8** Example 2-8 125.5±3.1** Example 3-6 126.2±2.6** Example 3-7 119.1±3.3** Example 3-8 121.9±3.7**

[Example 6] Inhibitory Effect of Hot Water and Ethanol Extract on Root Protein Degradation of Cudrania Leaves

L6 myoblast (ATCC), a muscle cell, was placed in a 6-well plate with DMEM (Hyclone) containing 10% FBS (Hyclone) at 1 × 10 ⁵ cells/mL. When the cell density reached about 80-85%, the medium in the well was removed and the cells were treated with DMEM (Hyclone) containing 2% HS (Hyclone) to induce myotube differentiation. Differentiation was carried out for a total of 6 days by replacing with a new medium once every 2 days. After differentiation, hot water of Cudrania leaves prepared in Examples 1-1 to 1-5 in DMEM (Hyclone) containing 50 ng/mL tumor necrosis factor alpha (TNF-α; PeproTech, Rocky Hills, NJ, USA) And ethanol extracts were each dissolved in DMEM (Hyclone) at 40 μg/mL, and then treated on cells. After 12 hours, total RNA was isolated using a TRIzol reagent (Takara, Otsu, Japan). The isolated total RNA was quantified using NanoDrop 1000; Thermo Fisher Scientific Inc., Waltham, MA, USA. 16 μL of quantified RNA was prepared at 42°C, 55 minutes and 70°C, 15 minutes using Reverse Transcriptase Premix (ELPIS-Biotech) and PCR machine (Gene Amp PCR System 2700; Applied Biosystems, Foster City, CA, USA). It was synthesized with cDNA under conditions. Of the generated cDNA of 16 μL, 1 μL of cDNA, the following specific primers (Bioneer, Daejeon, Korea) and PCR premix (ELPIS-Biotech) were used for 30 seconds at 95°C, 1 minute at 60°C, 1 minute at 72°C. PCR was performed by repeating 30 times.

MuRF1

Forward primer: 5'-CCGGACGGAAATGCTATGGA-3' (SEQ ID NO: 1)

Reverse primer: 5'-AGCCTGGAAGATGTCGTTGG-3' (SEQ ID NO: 2)

Atrogin-1

Forward primer: 5'-GTTACTGCAACAAGGAGAATCTGTT-3' (SEQ ID NO: 3)

Reverse primer: 5'-CCGTATGAGTCTTATGTTTTGCTGG-3' (SEQ ID NO: 4)

β-Actin:

Forward primer: 5'-TGACAGGATGCAGAAGGAGATTAC-3' (SEQ ID NO: 5)

Reverse primer: 5'-TAAAACGCAGCTCAGTAACAGTC-3' (SEQ ID NO: 6)

The amplified cDNA as a result of PCR was separated by electrophoresis with 1.5% agarose gel, and the cDNA band was confirmed using a G;BOX EF imaging system (Syngene).

As a result, as shown in FIG. 2, it was found that the mRNA expression of atrogin-1 and MuRF1 increased by treatment with TNF-α was decreased by hot water and ethanol extract of Cudrania tree leaves. This means that the hot water and ethanol extract of Cudrania tree leaves of the present invention have excellent ability to inhibit muscle protein degradation in muscle cells.

[Example 7] Inhibitory effect of hot water and ethanol extract of Cudrania tree fruit on muscle protein degradation

Except that the hot water and ethanol extracts of Cudrania fruit prepared in Examples 2-1 to 2-5 were each treated at 40 μg/mL, and the procedure was carried out in the same manner as in Example 6.

As a result, as shown in FIG. 3, when TNF-α was treated, mRNA expression of atrogin-1 and MuRF1 was increased compared to the control, but when treated with hot water and ethanol extract of Cudrania chinensis, all compared to the TNF-α treatment group It was confirmed that it decreased. This means that the hot water and ethanol extract of Cudrania tree fruit of the present invention have excellent ability to inhibit muscle protein degradation in muscle cells.

[Example 8] Inhibitory Effect of Hot Water and Ethanol Extract on Root Protein Degradation of Cudrania Branch

Except that the hot water and ethanol extract of Cudrania tree branches prepared in Examples 3-1 to 3-5 were each treated by 40 μg/mL, and the procedure was carried out in the same manner as in Example 6.

As a result, as shown in FIG. 4, when TNF-α was treated, mRNA expression of atrogin-1 and MuRF1 was increased compared to the control group, but when treated with hot water and ethanol extract of Cudrania tree branch, all compared to the TNF-α treatment group. It was confirmed that it decreased. This means that the hot water and ethanol extract of Cudrania tree branch of the present invention have excellent ability to inhibit muscle protein degradation in muscle cells.

[Example 9] Effect of Cudrania tree extract on inhibiting muscle protein degradation

Cudrania leaf ethyl acetate, hexane, ultra-high pressure, subcritical, and supercritical extracts of Examples 1-6 to 1-10; Cudrania fruit super-high pressure, subcritical, supercritical extracts of Examples 2-6 to 2-8; Except that the ultra-high pressure, subcritical, and supercritical extracts of Cudrania tree stems of Examples 3-6 to 3-8 were each treated with 40 μg/mL, and repeated three times in the same manner as in Example 6 Proceeded. Next, the band density of MuRF1 and atrogin-1 mRNA was measured using the Image J program (National Institute of Health, Bethesda, MD, USA), and then each measured value was averaged by calculating the percentage (%) for the control group. Expressed as standard deviation.

As a result, as shown in Table 2, the mRNA expression of atrogin-1 and MuRF1 was significantly increased ( ^## p <0.01) by treatment with TNF-α, but all were significant ( ^** p <0.01). This means that the Cudrania tree leaf extract of the present invention has excellent ability to inhibit muscle protein degradation in muscle cells.

Experimental group Relative atrogin-1
Expression amount (%) Relative atrogin-1
Expression amount (%) TNF-α 347.6±36.9** 338.0±26.1** Example 1-6 150.7±45.8** 182.7±31.3** Example 1-7 166.7±39.0** 176.0±36.8** Example 1-8 149.3±45.2** 183.3±29.3** Example 1-9 165.8±32.1** 190.3±23.5** Example 1-10 147.1±42.5** 162.5±34.9** Example 2-6 185.0±38.4** 204.8±20.4* Example 2-7 190.6±29.4** 210.5±30.5** Example 2-8 180.7±46.8** 198.4±28.5** Example 3-6 178.9±38.4** 190.6±40.8** Example 3-7 180.4±32,9** 217.5±36.9** Example 3-8 177.2±42.8** 210.6±38.3**

[Example 10] Effect of increasing muscle function and muscle mass of 50% ethanol extract of Cudrania tree leaves in an animal model

<10-1> Animal breeding and induction of muscle atrophy

As experimental animals, 7-week-old male mice (C57BL/6J; DBL, Korea) were purchased and tested. The environment of the breeding room of all animals was maintained at a temperature of 23±2℃ and a relative humidity of 55±10%. Before the start of the experiment, a total of 20 mice were randomly divided into 5 mice per group. After acclimating for 1 week, anesthesia was induced by intraperitoneal injection of 325 mg/kg of tribromoethanol (Sigma-Aldrich). After anesthesia, the right hindlimb gastrocnemius muscle and right sole of the rats in the muscle atrophy group and the sample administration group were treated with a stapler using a skin stapler (Unidus, Chungcheongbuk-do, Korea). It was damaged and prevented the right hind limb from moving, and this condition was maintained for a week. After a week, the stapler core fixed on the calf muscle and the sole of the foot was removed, and the 50% ethanol extract of Cudrania leaves of Example 1-3 was orally for 7 days daily at a concentration of 50 mg/kg or 150 mg/kg for another week. Was administered. At this time, the normal group and the muscular atrophy group were orally administered with saline instead of the sample.

<10-2> Confirmation of muscle strength improvement effect of 50% ethanol extract of Cudrania tree leaves

After the oral administration period was over, the muscle strength of the mice was measured using a muscle strength meter (Panlab, Barcelona, Spain). The tail of the rat was pulled with a constant force until the rat released the youngest of the strength tester, and a total of 5 consecutive tests were performed per animal.

As a result, as shown in FIG. 5, muscle strength was significantly decreased in the muscular atrophy group compared to the normal group ( ^# p <0.05), but strength was reduced by treatment with 50 mg/kg or 150 mg/kg of Cudrania leaves 50% ethanol extract. It was confirmed that this increased significantly ( ^* p <0.05, ^** p <0.01). This means that the 50% ethanol extract of Cudrania leaves of the present invention has an excellent effect of increasing the muscle strength reduced due to muscle atrophy.

<10-3> Effect of 50% Ethanol Extract of Cudrania Tree Leaves on Increased Muscle Volume

Prior to sacrifice, the mouse was respiratory anesthetized with isoflurane and the volume and density of the right hind limb muscle were measured using positron emission tomography/computed tomography/single photon emission tomography (microPET/CT/SPECT; Siemens Inveon, Knoxville, TN, USA). I did.

As a result, as shown in FIG. 6, the muscle volume of the muscular atrophy group was significantly reduced ( ^## p <0.01) compared to the normal group, but 50 mg/kg or 150 mg/kg of Cudrania leaves 50% ethanol extract was treated. It was confirmed that the muscle volume increased significantly ( ^** p <0.01). This means that the 50% ethanol extract of Cudrania leaves of the present invention has an excellent effect of increasing the volume of muscles reduced due to muscular atrophy.

<10-3> Confirmation of the effect of 50% ethanol extract of Cudrania tree leaves on increasing muscle weight

After the muscle strength measurement was completed, the experimental animal was intraperitoneally injected with 325 mg/kg of tribromomethanol (Sigma-Aldrich) and sacrificed through cardiac blood collection after anesthesia. After confirming that the heartbeat stopped, the uninjured tibialis anterior muscle was removed from the right hind limb and the weight was measured.

As a result, as shown in FIG. 7, the weight of the tibialis anterior muscle of the muscular atrophy group was significantly reduced ( ^## p <0.01) compared to the normal group, but 50% ethanol extract of Cudrania leaves 50 mg/kg or 150 mg/kg It was confirmed that the weight during treatment increased significantly ( ^** p <0.01; ^** p <0.01). This means that the 50% ethanol extract of Cudrania leaves of the present invention has an excellent effect of increasing the weight of the reduced muscle due to muscle atrophy.

[Example 11] Effect of increasing muscle function and muscle mass of Cudrania tree crushed product and Cudrania tree hot water extract in an animal model

500 mg/kg of dried pulverized Cudrania leaves and 150 mg/kg of hot water extract of Cudrania leaves of Example 1; Cudrania fruit dried pulverized product 500mg/kg and the Cudrania fruit hot water extract of Example 2 150mg/kg; After administration of 500mg/kg of dried pulverized Cudrania tree branch and 150mg/kg of hot water extract of Cudrania tree branch of Example 3 in the same manner as in Example 10, muscle strength and muscle weight were measured, respectively.

As a result, as shown in Table 2, muscle strength ( ^# p <0.05) and muscle weight ( ^## p <0.01) were significantly reduced in the muscular atrophy group compared to the normal group, but muscle strength and muscle weight in all sample treatment groups were significantly reduced. Compared to the muscle atrophy group, it was confirmed that it increased significantly ( ^* p <0.05, ^** p <0.01). This means that the pulverized product and hot water extract of Cudrania tree leaves, fruits, and stems of the present invention have excellent effects of increasing muscle strength and muscle weight reduced due to muscle atrophy.

Experimental group Muscle strength (g) Muscle weight (mg) Normal 196.3±12.9 54.7±4.2 Muscular atrophy 170.6±10.8 ^# 43.8±3.3 ^## Cudrania Leaf Crush 194.9±10.4** 51.2±4.9** Cudrania Leaf Hot Water Extract 192.8±8.2** 53.2±5.3** Cudrania fruit crushed product 189.5±9.0* 49.9±4.6* Cudrania fruit hot water extract 190.4±10.5** 52.8±5.0** Cudrania branch crushed product 188.6±8.2* 49.0±3.7* Cudrania branch hot water extract 193.2±10.1** 53.1±5.1**

Hereinafter, examples of preparation of pharmaceuticals, foods, or cosmetics containing the Cudrania chinensis extract according to the present invention as an active ingredient will be described, but the present invention is not intended to limit them, but is intended to be described in detail. The conventional method of preparing pharmaceuticals, foods, or cosmetic compositions of Preparation Examples 1 to 3 according to the following composition components and composition ratios using Cudrania tree crushed product or Cudrania tree extract having excellent muscle disease prevention and treatment, or muscle function improvement effect It was prepared according to.

[Production Example 1] Pharmaceuticals

<1-1> powder

After mixing 50 mg of Cudrania tree extract of the present invention and 2 g of crystalline cellulose, the powder was prepared by filling it in an airtight cloth according to a conventional powder preparation method.

<1-2> tablet

After mixing the Cudrania tree, Cudrania tree pulverized product or Cudrania tree extract of the present invention, 50 mg, 400 mg of crystalline cellulose, and 5 mg of magnesium stearate, tablets were prepared by tableting according to a conventional tablet manufacturing method.

<1-3> Capsule

Cudrania tree, Cudrania tree crushed product or Cudrania tree extract of the present invention 30 mg, whey protein 100 mg, crystalline cellulose 400 mg, magnesium stearate 6 mg are mixed, and then filled into gelatin capsules according to a conventional capsule preparation method, Was prepared.

[Production Example 2] Food

<2-1> Manufacture of health food

Cudrania tree crushed product of the present invention or Cudrania tree extract 1000 mg, vitamin A acetate 70 ug, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, vitamin B12 0.2 ug, vitamin C 10 mg, Biotin 10 ug, nicotinic acid amide 1.7 mg, folic acid 50 ug, calcium pantothenate 0.5 mg, ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, potassium monophosphate 15 mg, calcium dibasic 55 mg, citric acid It can be prepared by mixing 90 mg of potassium, 100 mg of calcium carbonate, and 24.8 mg of magnesium chloride, and the mixing ratio may be arbitrarily modified. After mixing the above ingredients according to a general health food manufacturing method, the granules are It can be prepared and used for preparing a health food composition according to a conventional method.

<2-2> Manufacture of health drinks

After adding purified water to Cudrania tree extract 1000 mg, citric acid 1000 mg, oligosaccharide 100 g, plum concentrate 2 g, taurine 1 g, total 900 mL of the above ingredients are mixed according to a conventional health drink manufacturing method, and then about 1 After stirring and heating at 85 for a period of time, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and then stored in a refrigerator, which can be used to prepare a health drink composition.

<2-3> Chewing gum

A chewing gum was prepared by a conventional method by combining 20% by weight of gum base, 76.9% by weight of sugar, 1% by weight of flavor, 2% by weight of water, and 0.1% by weight of the Cudrania tree extract of the present invention.

<2-4> candy

Sugar 60% by weight, starch syrup 39.8% by weight, 0.1% by weight of flavor and 0.1% by weight of the Cudrania extract of the present invention were mixed to prepare a candy by a conventional method.

<2-5> biscuit

Power Level 1 25.59% by weight, Gravity Level 1 22.22% by weight, sugar 4.80% by weight, salt 0.73% by weight, glucose 0.78% by weight, palm shortening 11.78% by weight, ammonium 1.54% by weight, sodium bicarbonate 0.17% by weight, sodium bisulfite 0.16% by weight , Rice flour 1.45% by weight, vitamin B 0.0001% by weight, milk flavor 0.04% by weight, water 20.6998% by weight, whole milk powder 1.16% by weight, substitute powdered milk 0.29% by weight, monobasic calcium phosphate 0.03% by weight, spray salt 0.29% by weight and spray A biscuit was prepared by a conventional method by blending 7.27% by weight of milk and 0.8301% by weight of the pulverized Cudrania tree or Cudrania tree extract of the present invention.

[Production Example 3] Cosmetics

<3-1> Nutritional lotion (milk lotion)

Nutrient cosmetic water was prepared according to a conventional method by using the Cudrania tree extract of the present invention according to the nutritional cosmetic water formulation ratio in Table 3 below.

Ingredients Manufacturing Example 3-1
(weight%) Cudrania tree extract 2.0 Squalane 5.0 Beeswax 4.0 Polysorbate 60 1.5 Sorbitansquioleate 1.5 Floating paraffin 0.5 Caprylic/Capric Triglyceride 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservatives, colors, flavors Appropriate amount Purified water to 100

<3-2> Flexible lotion (skin lotion)

The soft cosmetic water was prepared according to a conventional method by using the Cudrania tree extract of the present invention according to the ratio of the soft cosmetic water formulation shown in Table 4 below.

Ingredients Manufacturing Example 3-2
(weight%) Cudrania tree extract 2.0 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 PEG 12 nonylphenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservatives, colors, flavors Appropriate amount Purified water to 100

<3-3> Nutrition cream

A nutrient cream was prepared according to a conventional method by using the Cudrania tree extract of the present invention according to the nutritional cream formulation ratio of Table 5 below.

Ingredients Manufacturing Example 3-3
(weight%) Cudrania tree extract 2.0 Polysorbate 60 1.5 Sorbitansquioleate 0.5 PEG60 hydrogenated castor oil 2.0 Floating paraffin 10 Squalane 5.0 Caprylic/Capric Triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 antiseptic Appropriate amount Pigment Appropriate amount Spices Appropriate amount Purified water to 100

<3-4> Massage cream

A massage cream was prepared according to a conventional method by using the pulverized Cudrania tree or Cudrania tree extract of the present invention according to the ratio of the massage cream formulation in Table 6 below.

Ingredients Manufacturing Example 3-4
(weight%) Cudrania pulverum or Cudrania tree extract 1.0 Beeswax 10.0 Polysorbate 60 1.5 PEG 60 hydrogenated castor oil 2.0 Sorbitansquioleate 0.8 Floating paraffin 40.0 Squalane 5.0 Caprylic/Capric Triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, colors, flavors Appropriate amount Purified water to 100

<3-5> pack

A pack was prepared according to a conventional method by using the pulverized Cudrania tree or Cudrania tree extract of the present invention according to the pack formulation ratio of Table 7 below.

Ingredients Manufacturing Example 3-5
(weight%) Cudrania pulverum or Cudrania tree extract 1.0 Polyvinyl alcohol 13.0 Sodium carboxymethyl cellulose 0.2 glycerin 5.0 Allantoin 0.1 ethanol 6.0 PEG 12 nonylphenyl ether 0.3 Polysorbate 60 0.3 Preservatives, colors, flavors Appropriate amount Purified water to 100

<3-6> gel

A gel was prepared according to a conventional method using the Cudrania tree extract of the present invention according to the gel formulation ratio of Table 8 below.

Ingredients Manufacturing Example 3-6
(weight%) Cudrania tree extract 0.5 Sodium ethylenediamine acetate 0.05 glycerin 5.0 Carboxyvinyl polymer 0.3 ethanol 5.0 PEG 60 hydrogenated castor oil 0.5 Triethanolamine 0.3 Preservatives, colors, flavors Appropriate amount Purified water to 100

<110> Industry-Academic Cooperation Foundation, Yonsei University <120> Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Cudrania tricuspidata <130> HPC9400 <160> 6 <170> KopatentIn 2.0 <210> 1 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Forward primer for Atrogin-1 <400> 1 gttactgcaa caaggagaat ctgtt 25 <210> 2 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for Atrogin-1 <400> 2 ccgtatgagt cttatgtttt gctgg 25 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer for MuRF-1 <400> 3 ccggacggaa atgctatgga 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for MuRF-1 <400> 4 agcctggaag atgtcgttgg 20 <210> 5 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for beta-Actin <400> 5 tgacaggatg cagaaggaga ttac 24 <210> 6 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for beta-Actin <400> 6 taaaacgcag ctcagtaaca gtc 23

Claims (8)

Cudrania tricuspidata ( Cudrania tricuspidata ) for improving or preventing muscle disease containing as an active ingredient, or a food composition for improving muscle function.
The method of claim 1,
The Cudrania tricuspidata is a pulverized product of leaves, fruits, or branches of Cudrania tricuspidata ,
The Cudrania tree extract is a food composition for improving or preventing muscle disease, or improving muscle function, characterized in that obtained by extracting leaves, fruits, or branches of Cudrania tree.
The method of claim 1,
The Cudrania tree extract is obtained by extracting Cudrania tree with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid, and a supercritical fluid, for improving or preventing muscle diseases, Or a food composition for improving muscle function.
The method of claim 3,
The organic solvent is an alcohol having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane ( Food composition for improving or preventing muscle disease, or improving muscle function, characterized in that it is at least one solvent selected from the group consisting of hexane), cyclohexane and petroleum ether.
The method according to any one of claims 1 to 4,
The muscle disease is characterized in that at least one selected from the group consisting of atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia. Food composition for improving or preventing muscle disease, or for improving muscle function.
Cudrania tricuspidata ( Cudrania tricuspidata ) a pharmaceutical composition for the treatment or prevention of muscle diseases containing as an active ingredient.
Cudrania tricuspidata ( Cudrania tricuspidata ) for improving or preventing muscle disease containing as an active ingredient, or cosmetic composition for improving muscle function.
Cudrania tricuspidata ( Cudrania tricuspidata ) for improving or preventing muscle disease containing as an active ingredient, or feed additive for improving muscle function.

Images